Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma
TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.
Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.
"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."
Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.
"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."
Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.
About Ripple Therapeutics
Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com
Piper Sandler acted as the exclusive financial advisor to Ripple.
For further information:
Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988
SOURCE: Ripple Therapeutics
View the original press release on accesswire.com
Ripple Therapeutics
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Opti Digital Breaks Down the Biggest AdTech Trends in 202518.10.2024 03:40:00 CEST | Press release
As the ad tech landscape evolves, 2025 promises to be a pivotal year for digital advertising, with key trends already emerging. BARCELONA, SPAIN / ACCESSWIRE / October 18, 2024 / Magali Quentel-Reme, CEO of Opti Digital; Mohsin Pervez, Senior Director of Platform Solutions and Operations, EMEA at PubMatic; and Langdon Miller, Director of Programmatic at Brainly, share their insights on the future of the AdTech landscape and the key trends set to shape programmatic in 2025. Addressability Solution With over 50% of third-party cookies already phased out and Google's pivotal July 2024announcement granting users control over cookie settings, the need for effective alternatives is more critical than ever. Langdon Miller, Director of Programmatic at Brainly, explains that "the integration of probabilistic and deterministic IDs, first-party data, contextual segmentation, and bid decoration has led to sustained performance and increased yield." This is echoed on the buy side, with a growing re
Participation in the Multilateral System Remains High as Performance Drops, New Index Finds17.10.2024 13:00:00 CEST | Press release
The Multilateralism Index 2024 reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined. WASHINGTON, DC / ACCESSWIRE / October 17, 2024 / Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces. Multilateralism Index 2024 Report An image of the front cover of the Multilateralism Index 2024 Report Key results The performance of the multilateral system declined across all five domains examined. Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022. Climate action and human rights also saw significant declines in performance, despite i
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells16.10.2024 09:00:00 CEST | Press release
ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos' Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063 LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel dise
Probabl (The Official Operator of the Scikit-Learn Brand) Selects Kryterion to Provide Certification to Millions of Data Scientists in Machine Learning16.10.2024 08:40:00 CEST | Press release
HARROW, UK / ACCESSWIRE / October 16, 2024 / Kryterion, a leader in certification test development and delivery solutions, was selected by Probabl, the official operator of the scikit-learn brand, to deliver the first-ever official certification programme targeting millions of data scientists. The scikit-learn software library has registered over 1.5 billion downloads and is the gold standard for open-source machine learning in the Python ecosystem, underpinning over 1 million global projects. Kryterion's proven track record as a secure, scalable certification platform makes it the ideal partner for delivering this groundbreaking programme. Kryterion & Probabl Probabl and Kryterion will support the global data science community by offering the first globally recognised certification in scikit-learn. As the official operator of the scikit-learn brand, Probabl is spearheading the initiative to provide structured certification across three key tiers: associate, professional, and expert. T
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History16.10.2024 06:00:00 CEST | Press release
LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom